Articles tagged with Amyloids
A team at Baylor College of Medicine found that human NANOG's 'super stickiness' enables it to form large aggregates at low concentrations, which interact with chromatin to activate a pluripotent state. This process involves reshaping the genomic landscape and turning on genes involved in pluripotency.
Research suggests that EMFs can cause Alzheimer's disease by building up calcium levels in brain cells. This increase leads to changes in the brain, which develop conditions for Alzheimer's. The study highlights the importance of reducing EMF exposure to prevent or delay the onset of Alzheimer's.
Researchers at UCLA have discovered that amyloid fibrils in the brains of patients with frontotemporal degeneration are composed of the protein TMEM106B, not TDP-43 as expected. This finding may lead to new focus on TMEM106B in FTLD and similar brain diseases.
Researchers found a clear link between elevated amyloid beta levels and the development of anxiety and apathy in Alzheimer's patients. These symptoms occur mainly due to underlying brain changes, not psychological reactions. The study suggests that psychiatric symptoms could be used as alternative outcome measures in treatment trials.
Researchers found a higher number of small HDL particles in cerebrospinal fluid is associated with better cognitive performance and lower risk for Alzheimer's disease. These particles may play a key role in clearing amyloid beta peptides, which contribute to the disease.
Researchers found that high levels of both amyloid and tau proteins impair memory functions, but only when amyloid burden is also high. The study suggests that anti-amyloid therapies may be beneficial in reducing memory impairment in the early stages of Alzheimer's disease.
A new study identifies the age-dependent formation of TMEM106B amyloid filaments in human brains, which may not be linked to neurodegenerative diseases. Researchers found these protein structures in older but not younger individuals, suggesting a potential role in aging and other pathologies.
Researchers at Lewis Katz School of Medicine identify reduced efficiency of protein transport system as key factor in Alzheimer-like changes. The study suggests that targeting the retromer complex could lead to new treatments for Down syndrome-related dementia.
Researchers identified peripheral tissues as source of blood amyloid beta, which regulates blood glucose levels and suppresses insulin secretion. The study suggests a possible mechanism linking type 2 diabetes to Alzheimer's disease development.
A new blood test developed at Washington University School of Medicine has proven highly accurate in detecting early signs of Alzheimer’s disease, with a 93% accuracy rate. The test assesses amyloid plaques based on the ratio of A´2 and A´0 proteins in the blood, providing a low-cost alternative to expensive brain scans and spinal taps.
Researchers developed a vortex microscope that captures detailed motion and rotation of molecules in liquid. The technique provides unprecedented insight into molecular dynamics, enabling the study of diseases like Alzheimer's.
Researchers introduce a genetic mutation that reduces Alzheimer's risk by preventing amyloid plaque formation. The mutation, found in Icelanders, has no known disadvantage and may be used to treat familial and sporadic forms of the disease.
Research at Rensselaer Polytechnic Institute found that the circadian system influences the immune cells' clearance of Amyloid-Beta 42, a key protein linked to Alzheimer's disease. Boosting daily oscillations could increase clearance and prevent brain damage.
A UCLA-led study found that aducanumab's ancillary care services, such as MRIs and neurologist visits, account for nearly 20% of total Medicare costs. The estimated annual spending on the drug could increase Medicare premiums.
Researchers at West Virginia University are investigating the link between chronic stress and Alzheimer's disease using animal models. They aim to understand how xanthine oxidase may sabotage brain blood vessels in Alzheimer's patients, and explore whether a medication can block this pathway to keep the brain healthy.
Researchers found that the SARS-CoV-2 N-protein accelerates the formation of amyloid fibrils in test tube experiments, interacting with α-synuclein protein. This interaction may contribute to the development of Parkinson's disease in COVID-19 patients.
Researchers found that genomic screening can identify patients at risk for heart disease due to amyloidosis. The study used data from the MyCode Community Health Initiative and electronic health records to determine how often patients with specific transthyretin variants showed signs of cardiomyopathy.
Researchers analyzed similarities and differences of corpora amylacea in various tissues, revealing they contain waste products packed in a glycan skeleton. The term 'wasteosomes' is proposed for these structures, emphasizing their function.
Researchers are modifying an arm of a worldwide clinical trial to evaluate a combination of drugs targeting two brain proteins: amyloid and tau. The Tau NexGen Trial aims to test the effectiveness of these treatments in slowing disease progression by targeting both Alzheimer's disease pathologies.
Researchers at Shinshu University discovered a new type of amyloidosis associated with duodenal neuroendocrine tumors that produce somatostatin. Laser microdissection and liquid chromatography-tandem mass spectrometry techniques were used to identify the amyloid formation.
Scientists at Gladstone Institutes discovered that non-convulsive epileptic activity drives chronic brain inflammation in Alzheimer's models, which can be reversed by eliminating protein tau or using the anti-epileptic drug levetiracetam. This link between brain networks and immune cells may hold promising treatments for Alzheimer's di...
Researchers at Uppsala University have designed new antibodies that bind to both large and small aggregates of the amyloid-beta protein, potentially providing a more effective treatment for Alzheimer's disease. The new antibody format is stronger in binding to clumps and can also target smaller aggregates.
A new algorithm uses amyloid PET scans to gauge brain levels of Alzheimer's protein and estimate when symptoms will arise. By analyzing age and single scan data, the algorithm yields an estimate of how far a person has progressed toward dementia.
A new study found that cholesterol produced by astrocytes is required for controlling amyloid beta production, leading to the accumulation of insoluble plaques. Blocking this cholesterol manufacturing reduced amyloid beta production in lab mice, offering a potential strategy against Alzheimer's disease.
Researchers discovered that amyloid beta peptides, which form gummy plaques in Alzheimer's disease, go through several intermediate stages of frustration as they dock and lock to growing fibrils. This suggests that drugs might be developed to stabilize the fibril tips and block further aggregation by targeting the 'Achilles' heel' of f...
Georgia State University researcher Vince Calhoun has received a $3.5 million grant to develop new methods for capturing dynamic connectivity in the brain and identifying biomarkers for early detection of Alzheimer's disease. The researchers aim to analyze real-time connectivity patterns to predict future cognitive decline.
The Alzheimer's Drug Discovery Foundation has provided NeuroVision Imaging Inc. with additional funding to accelerate the development of a novel blood-based lab test that can predict dementia before clinical onset. This technology has the potential to make diagnostic testing more practical, less invasive and less costly.
A new study from University of California - San Diego suggests that protein deposits in the retina and brain may be a sign of Alzheimer's disease risk. Retinal imaging may potentially serve as an early biomarker for detecting AD risk, offering a non-invasive alternative to traditional brain scans.
Researchers at UC San Diego have discovered the main components driving amyloid beta-associated synapse degeneration in Alzheimer's disease. They found that blocking a toxic signaling pathway can protect synapses and preserve cognitive function, offering a potential therapeutic agent.
A study from Lund University reveals that Alzheimer's protein accumulates inside nerve cells, leading to increased production and potentially devastating effects. The research suggests that targeting misfolded amyloid-beta within cells may be a more effective approach than focusing on plaques outside the brain.
Researchers have successfully characterized a new form of toxic Aβ42 fibrils in Alzheimer's disease using sensitivity-enhanced solid-state NMR spectroscopy. The study paves the way for novel therapeutic strategies targeting these aggregates that drive AD progression.
A team of researchers at Washington University in St. Louis has developed artificially designed, amyloid-silk hybrid protein produced in engineered bacteria that surpasses the strength and toughness of natural spider silks, as well as steel and Kevlar.
Researchers at Imperial College London have created a metal-based molecule that inhibits the build-up of amyloid-β peptides associated with Alzheimer's disease. The molecule was shown to be non-toxic to human brain-like cells and cross the blood-brain barrier in mice using focused ultrasound.
Aducanumab, a monoclonal antibody approved for Alzheimer's disease, has no proven benefits in treating cerebral amyloid angiopathy (CAA), according to doctors. The FDA approval opens the door for off-label use, but experts caution against it due to safety concerns and lack of evidence.
Nanosized molecules of a particular chemical element can inhibit the formation of plaque in brain tissues, providing hope for novel treatments of neurodegenerative diseases. The discovery was made by researchers at Umeå University in collaboration with colleagues in Croatia and Lithuania.
Researchers have developed a new mouse model that mimics Alzheimer's neurodegeneration without relying on the pathogenic proteins amyloid or Tau. The GluN3A knockout mouse model highlights the role of calcium and neuronal hyperactivity in driving neurodegeneration, providing potential leads for new treatments and preventive strategies.
Researchers at UC University challenge prevailing Alzheimer's theory by discovering that normalizing brain protein levels can prevent cognitive impairment. The study found a correlation between high levels of soluble amyloid-beta peptide and normal cognition, suggesting future therapies should focus on replenishing these proteins.
Researchers at Boston University School of Medicine discovered that charged biopolymers like heparan sulfate and heparin accelerate amyloid aggregation in various organs. This understanding will guide targeted drug design for deadly diseases such as Alzheimer's, Parkinson's, and type-2 diabetes.
Researchers at Southern Methodist University have found that P-glycoprotein can transport amyloid-β proteins out of the brain, which are associated with Alzheimer's disease. This discovery could lead to new treatments for the disease affecting nearly 6 million Americans.
A study by Aarhus University suggests that changes in lipid composition within the brain cell membrane can weaken the protective effect of a protein dimerization process, leading to increased release of toxic amyloid-beta peptides. The researchers propose targeting lipid modulation as a novel strategy for Alzheimer's disease therapeutics.
A study published in Cell Reports has pinpointed a small group of immune cells in the brain that play a crucial role in Alzheimer's disease progression. By targeting these senescent microglia, researchers may be able to slow down disease acceleration and develop new treatment options.
Researchers at St. Petersburg State University have created a new theory and experimental methods to separate spectral signals from amyloid fibrils, overcoming obstacles faced by previous studies. This breakthrough may aid in the development of new drugs for neurodegenerative diseases.
A team of scientists has found the gene expression signatures underlying microglia associated with amyloid plaque phagocytosis. The findings suggest a new target for interventions to address the underlying disease mechanism of Alzheimer's Disease.
Researchers at MGH have discovered the role of mitochondria-associated endoplasmic reticulum membranes (MAMs) in forming amyloid beta in axons and neuronal processes. The study suggests that targeting sigma-1 receptors or inhibiting palmitoylation may reduce Abeta production, providing a potential therapeutic strategy for Alzheimer's d...
A new study suggests that consuming a Mediterranean diet rich in fish, vegetables, and olive oil can help prevent protein build-up and brain shrinkage associated with Alzheimer's disease. The research found that individuals who followed the Mediterranean diet more closely had lower levels of amyloid and tau biomarkers and improved cogn...
A new NIH-funded study in mice suggests that enhancing the brain's lymphatic system may lead to better clinical outcomes for Alzheimer's disease patients. The study found that treatments such as immunotherapies BAN2401 or aducanumab might be more effective when the brain's lymphatic system can better drain amyloid-beta protein.
Researchers at the University of Helsinki found a link between a gene defect and severe epilepsy in Parson Russell Terrier puppies. The PITRM1 gene mutation causes mitochondrial dysfunction, leading to neurodegeneration and seizures.
Researchers from University of Bath and ISIS Neutron and Muon Source invent technique to directly measure amyloid fibril growth rate in solution. This breakthrough is crucial for understanding the diseases associated with amyloid fibrils, which are deposits of proteins linked to Alzheimer's, Parkinson's, and Type 2 diabetes.
Researchers find that microglia promote the formation of dense-core plaques as part of a defense mechanism, clearing debris from neurons and potentially causing cell death. This discovery suggests that treatments targeting these protective plaques may be more effective than destroying them.
Researchers developed a photo-oxygenation catalyst that destabilizes and removes amyloid plaques, enhancing immune system clearance. The treatment significantly reduced amyloid protein in mouse brains, with human brain samples supporting its potential use in humans.
A study by NYU College of Dentistry and Weill Cornell Medicine found that older adults with more harmful than healthy bacteria in their gums are more likely to have evidence for amyloid beta, a key biomarker for Alzheimer's disease. The researchers suggest that high levels of 'good' bacteria may be protective against Alzheimer's.
Researchers found a molecular link between Parkinson's disease and melanoma, with amyloid proteins α-synuclein and Pmel interacting in melanoma cells. This interaction may lead to reduced pigment production, contributing to the increased risk of melanoma in Parkinson's patients.
A study by Scripps Research Institute found that experimental antibody therapies for neurodegenerative diseases like Parkinson's and Alzheimer's may cause brain inflammation, potentially eroding their positive effects. The researchers used human brain cells to examine this effect, which was not seen in mouse studies.
Researchers found that supplement N-acetyl-cysteine prevents formation of amyloid proteins, potentially leading to treatments for certain forms of dementia. The study suggests that the supplement could reduce risk of strokes and brain hemorrhages in patients with hereditary cystatin C amyloid angiopathy.
A comprehensive mutation map of the amyloid beta peptide has been developed to predict whether specific mutations increase an individual's risk of developing Alzheimer's disease. The study found that certain mutations accelerate protein aggregation, leading to the formation of toxic plaques in the brain.
A new drug has been identified that can prevent Alzheimer's disease by modulating the enzyme involved in forming amyloid plaques. The drug was tested on rodents and monkeys, demonstrating safety and effectiveness in reducing Aβ42 production and plaque formation.
Researchers identified a new drug that modulates a key enzyme to prevent amyloid plaque formation, reducing or eliminating problematic protein fragments. The novel compound showed safety and effectiveness in rodent and monkey studies, suggesting potential as a therapy for Alzheimer's disease.
Researchers have developed a new technique using bowl-shaped nanoparticles to study Alzheimer's disease amyloid beta protein aggregates. The findings confirm multiple forms of these aggregates co-exist and not all convert into brain plaques, opening possibilities for diagnostic and treatment applications.
A study published in Neuropathology and Applied Neurobiology reveals that RAPGEF2 protein overexpression leads to synaptic damage and cognitive impairment in Alzheimer's disease. Silencing RAPGEF2 prevents synapse loss and cognitive decline, suggesting a potential therapeutic target for neurodegenerative diseases.
Researchers at WashU Medicine have identified an antibody that removes amyloid plaques from brain tissue and blood vessels, improving vessel function without raising the risk of brain bleeds. This breakthrough discovery offers a potentially safer approach to treating Alzheimer's disease and cerebral amyloid angiopathy.